JPWO2020132297A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132297A5 JPWO2020132297A5 JP2021531831A JP2021531831A JPWO2020132297A5 JP WO2020132297 A5 JPWO2020132297 A5 JP WO2020132297A5 JP 2021531831 A JP2021531831 A JP 2021531831A JP 2021531831 A JP2021531831 A JP 2021531831A JP WO2020132297 A5 JPWO2020132297 A5 JP WO2020132297A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- acid sequence
- tmmp
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 127
- 229920001184 polypeptide Polymers 0.000 claims 111
- 102000004196 processed proteins & peptides Human genes 0.000 claims 111
- 125000003275 alpha amino acid group Chemical group 0.000 claims 67
- 102000043129 MHC class I family Human genes 0.000 claims 26
- 108091054437 MHC class I family Proteins 0.000 claims 26
- 230000003213 activating effect Effects 0.000 claims 22
- 230000002519 immonomodulatory effect Effects 0.000 claims 22
- 102100022748 Wilms tumor protein Human genes 0.000 claims 18
- 101710127857 Wilms tumor protein Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 8
- 108010002350 Interleukin-2 Proteins 0.000 claims 7
- 102000000588 Interleukin-2 Human genes 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 208000026448 Wilms tumor 1 Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 2
- 238000012575 bio-layer interferometry Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000000833 heterodimer Substances 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782167P | 2018-12-19 | 2018-12-19 | |
| US62/782,167 | 2018-12-19 | ||
| US201962814684P | 2019-03-06 | 2019-03-06 | |
| US62/814,684 | 2019-03-06 | ||
| PCT/US2019/067575 WO2020132297A1 (en) | 2018-12-19 | 2019-12-19 | Multimeric t-cell modulatory polypeptides and methods of use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022515330A JP2022515330A (ja) | 2022-02-18 |
| JP2022515330A5 JP2022515330A5 (https=) | 2022-12-26 |
| JPWO2020132297A5 true JPWO2020132297A5 (https=) | 2022-12-26 |
| JP7549579B2 JP7549579B2 (ja) | 2024-09-11 |
Family
ID=71100921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531831A Active JP7549579B2 (ja) | 2018-12-19 | 2019-12-19 | 多量体ｔ細胞調節ポリペプチド及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20220112252A1 (https=) |
| EP (2) | EP4650365A3 (https=) |
| JP (1) | JP7549579B2 (https=) |
| KR (1) | KR20210104673A (https=) |
| CN (1) | CN113286609B (https=) |
| AU (1) | AU2019404285B2 (https=) |
| BR (1) | BR112021011814A2 (https=) |
| CA (1) | CA3113100A1 (https=) |
| DK (1) | DK3897701T3 (https=) |
| ES (1) | ES3052836T3 (https=) |
| IL (1) | IL281505B1 (https=) |
| MX (1) | MX2021007287A (https=) |
| MY (1) | MY206813A (https=) |
| PH (1) | PH12021500027A1 (https=) |
| SG (1) | SG11202103863UA (https=) |
| SI (1) | SI3897701T1 (https=) |
| TW (1) | TWI856047B (https=) |
| WO (1) | WO2020132297A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3019005A1 (en) * | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN116970059A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| TW201920249A (zh) | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| EP4149953A4 (en) * | 2020-05-12 | 2024-06-26 | Lg Chem, Ltd. | MULTIMER T CELL MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF |
| EP4182465A4 (en) * | 2020-07-14 | 2024-08-07 | Cue Biopharma, Inc. | T-CELL MODULATORY POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2022099157A1 (en) * | 2020-11-06 | 2022-05-12 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| JP2024512470A (ja) * | 2021-03-19 | 2024-03-19 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節ポリペプチド及びその使用方法 |
| JP2024518680A (ja) * | 2021-03-19 | 2024-05-02 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節ポリペプチド及びその使用方法 |
| WO2023081718A1 (en) * | 2021-11-04 | 2023-05-11 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN114805538B (zh) * | 2022-05-20 | 2023-06-09 | 广州智瓴生物医药有限公司 | 一种增强til功效的培养方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US9205144B2 (en) | 2011-06-03 | 2015-12-08 | Dana-Farber Cancer Institute, Inc. | Identification of conserved peptide blocks in homologous polypeptides |
| EP3769782A1 (en) * | 2013-01-15 | 2021-01-27 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| PL3157552T3 (pl) * | 2014-06-18 | 2020-05-18 | Albert Einstein College Of Medicine | Polipeptydy syntac i ich zastosowania |
| MY193723A (en) * | 2014-08-29 | 2022-10-27 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| CA2978186A1 (en) * | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| LT3377516T (lt) * | 2015-11-20 | 2022-09-26 | Memorial Sloan Kettering Cancer Center | Kompozicija vėžiui gydyti |
| CA3019005A1 (en) * | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN116970059A (zh) * | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| IL269000B2 (en) * | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| AU2018236461B2 (en) * | 2017-03-17 | 2025-03-27 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| TW201920249A (zh) * | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| EP3678691A4 (en) * | 2017-09-07 | 2021-06-09 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| EP3897690A4 (en) * | 2018-12-19 | 2022-09-28 | Cue Biopharma, Inc. | T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2020132365A2 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| WO2020132366A2 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| WO2021055594A1 (en) * | 2019-09-20 | 2021-03-25 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| US20230117521A1 (en) * | 2020-03-25 | 2023-04-20 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| TW202208395A (zh) * | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| JP2024512470A (ja) * | 2021-03-19 | 2024-03-19 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節ポリペプチド及びその使用方法 |
-
2019
- 2019-12-18 TW TW108146526A patent/TWI856047B/zh active
- 2019-12-19 PH PH1/2021/500027A patent/PH12021500027A1/en unknown
- 2019-12-19 EP EP25193554.0A patent/EP4650365A3/en active Pending
- 2019-12-19 EP EP19900784.0A patent/EP3897701B1/en active Active
- 2019-12-19 MX MX2021007287A patent/MX2021007287A/es unknown
- 2019-12-19 SG SG11202103863UA patent/SG11202103863UA/en unknown
- 2019-12-19 KR KR1020217015556A patent/KR20210104673A/ko not_active Ceased
- 2019-12-19 WO PCT/US2019/067575 patent/WO2020132297A1/en not_active Ceased
- 2019-12-19 AU AU2019404285A patent/AU2019404285B2/en active Active
- 2019-12-19 CA CA3113100A patent/CA3113100A1/en active Pending
- 2019-12-19 CN CN201980080657.4A patent/CN113286609B/zh active Active
- 2019-12-19 IL IL281505A patent/IL281505B1/en unknown
- 2019-12-19 DK DK19900784.0T patent/DK3897701T3/da active
- 2019-12-19 JP JP2021531831A patent/JP7549579B2/ja active Active
- 2019-12-19 SI SI201930988T patent/SI3897701T1/sl unknown
- 2019-12-19 MY MYPI2021001671A patent/MY206813A/en unknown
- 2019-12-19 BR BR112021011814A patent/BR112021011814A2/pt unknown
- 2019-12-19 ES ES19900784T patent/ES3052836T3/es active Active
-
2021
- 2021-05-21 US US17/326,837 patent/US20220112252A1/en not_active Abandoned
-
2024
- 2024-07-10 US US18/768,830 patent/US20250074960A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500855A5 (https=) | ||
| IL272085B2 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| Kelly et al. | A new human HLA class II-related locus, DM | |
| JP2019512222A5 (https=) | ||
| Acuto et al. | Purification and NH2-terminal amino acid sequencing of the beta subunit of a human T-cell antigen receptor. | |
| JPWO2020132297A5 (https=) | ||
| JP2020511949A5 (https=) | ||
| JP2010527919A5 (https=) | ||
| IL308851B2 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| JP2021505136A5 (https=) | ||
| JP2017519491A5 (https=) | ||
| RS55609B1 (sr) | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane | |
| US20250283037A1 (en) | Methods for stimulating and transducing t cells | |
| JPWO2020252418A5 (https=) | ||
| EA012507B1 (ru) | Высокоаффинные мелан-а т-клеточные рецепторы | |
| JPWO2021119429A5 (https=) | ||
| JPWO2020243315A5 (https=) | ||
| JP2023526149A (ja) | Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 | |
| JPWO2021055594A5 (https=) | ||
| JPWO2020257191A5 (https=) | ||
| GB2619410A (en) | Methods and compositions for cellular therapy | |
| JPWO2020132138A5 (https=) | ||
| GB2613722A (en) | Target-recognition of antigen-MHC complex reporter (tracer) platform | |
| JPWO2020181062A5 (https=) | ||
| RU2160447C2 (ru) | Способ идентификации веществ, потенциальных для лечения аутоиммунных заболеваний (варианты), высокоочищенная днк (варианты) и высокоочищенный полипептид (варианты) |